FDA clears multicenter IND application for PET imaging agent

02/2/2009 | Diagnostic Imaging

The FDA has approved an SNM-sponsored multicenter investigational new drug application for F-18-labeled 3'-deoxy-3'-fluorothymidine -- a PET imaging agent used in measuring tumor growth and response to therapy. The multicenter IND allows multiple generators of the FLT agent to be evaluated under a single application, resulting in cost and time savings.

View Full Article in:

Diagnostic Imaging

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC